Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of the National Institutes of Health’s All of Us million-person program ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best depressed stocks to invest in now. The US stocks ended 2024 with a ...

The Seattle Mariners are in agreement with free-agent infielder Jorge Polanco on a one-year, $7.75 million deal, two league sources told The Athletic on Thursday, offering some clarity during the ...

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...

Her work previously appeared in Newsweek. NBCUniversal via Getty Debbie Allen has been an icon of the stage and screen for more than four decades! The multi-hyphenate, who turns 75 on Jan. 16 ...

There's a new Little Debbie product coming to town, and the internet is already counting down to the mashup of two iconic flavors—peanut butter and chocolate. The snack brand unveiled its latest ...

The Astros have ongoing interest in Jorge Polanco, reports Brian McTaggart of MLB.com. According to Chandler Rome and Ken Rosenthal of The Athletic, Houston could experiment with Polanco in left ...

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals REGN, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of ...